Program
ENX-102
A development code.
Its studies are mostly in Generalized Anxiety Disorder · Phobia, Social, led by Engrail Therapeutics.
Furthest: phase 2, since Feb 18, 20233 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Engrail Therapeutics | 30 open or running | phase 2since Feb 18, 2023 | Feb 18, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 18, 2023First study: phase 2 study in Generalized Anxiety DisorderFirst studyNCT05749055 · 252 enrolled · United States
- Oct 20, 2024Phase 2 study in Generalized Anxiety DisorderNCT06653296 · 38 enrolled · United Kingdom
- Sep 24, 2025Phase 2 study in Phobia, SocialNCT07193563 · 47 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07193563Phobia, Social · United States | 2 | Completed | Mar 19, 2026 | 47 |
| NCT06653296Generalized Anxiety Disorder · United Kingdom | 2 | Completed | Jun 23, 2025 | 38 |
| NCT05749055Generalized Anxiety Disorder · United States | 2 | Completed | Sep 18, 2025 | 252 |
How it is read
Names in the registry
- “ENX-102”, 3 entries
Codes read as this program: ENX102.
Conditions, from the studies’ own filings
- Generalized Anxiety Disorder, 2 studies
- Phobia, Social, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.